脐带血源性产品Omidubicel的临床研发进展

doi:10.3877/cma.j.issn.2095-1221.2023.03.008

中华细胞与干细胞杂志(电子版) ›› 2023, Vol. 13 ›› Issue (03) : 178 -182. doi: 10.3877/cma.j.issn.2095-1221.2023.03.008

综述

脐带血源性产品Omidubicel的临床研发进展

崔燕妮, 任颜, 梁凤婷, 覃艳红, 王宏伟^†(

)

030001　太原，山西医科大学第二医院血液病研究所；030001　太原，血液病分子诊疗山西省重点实验室；030001　太原，山西省干细胞临床转化研发联合实验室
030001　太原，山西医科大学第二医院血液病研究所；030001　太原，血液病分子诊疗山西省重点实验室

收稿日期:2023-03-09 出版日期:2023-06-01
通信作者: 王宏伟
基金资助:
山西省中央引导地方科技发展资金项目(YDZJSX2021B009); 山西省医学重点科技项目计划(2021XM07)

Clinical research and development progress of cord blood-derived product Omidubicel

Yanni Cui, Yan Ren, Fengting Liang, Yanhong Tan, Hongwei Wang^†()

Institute of Hematology of the Second Hospital of Shanxi Medical University, Taiyuan 030001, China; Shanxi Provincial Key Laboratory of Molecular Diagnosis and Treatment of Hematology Diseases, Taiyuan 030001, China; Joint Laboratory of Stem Cell Clinical Transformation and Research in Shanxi Province, Taiyuan 030001, China
Institute of Hematology of the Second Hospital of Shanxi Medical University, Taiyuan 030001, China; Shanxi Provincial Key Laboratory of Molecular Diagnosis and Treatment of Hematology Diseases, Taiyuan 030001, China

Received:2023-03-09 Published:2023-06-01
Corresponding author: Hongwei Wang

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

崔燕妮, 任颜, 梁凤婷, 覃艳红, 王宏伟. 脐带血源性产品Omidubicel的临床研发进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2023, 13(03): 178-182.

Yanni Cui, Yan Ren, Fengting Liang, Yanhong Tan, Hongwei Wang. Clinical research and development progress of cord blood-derived product Omidubicel[J/OL]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(03): 178-182.

作为造血干细胞（HSC）的重要来源之一，脐带血的临床应用受到CD34⁺细胞剂量低、造血恢复缓慢和移植失败风险增加的限制。Omidubicel是利用烟酰胺（NAM）进行HSC体外扩增的脐带血细胞治疗产品，在同种异体HSC移植中比未经处理的脐带血植入速度更快，感染率更低。本文重点回顾Omidubicel在恶性血液病中的临床应用，总结该扩增策略的早期益处，但其对患者的长期影响仍需要大规模的临床研究进行观察。总而言之，Omidubicel的出现将扩增脐带血移植推向了移植治疗和再生医学的前沿。

关键词: Omidubicel, 脐带血, 造血干细胞, 体外扩增, 烟酰胺

The clinical application of umbilical cord blood as a source of hematopoietic stem cells (HSC) for transplantation is limited by the low dose of CD34⁺ cells, increased risk of graft failure and slow hematopoietic recovery. Omidubicel is a kind of Umbilical cord blood cell therapy product that expands hematopoietic stem cells in vitro by nicotinamide (NAM) . Compared with unmanipulated Umbilical cord blood, it has faster implantation speed and a lower infection rate in allogeneic hematopoietic stem cell transplantation. Here, we focus on reviewing the relevant data on the clinical application of Omidubicel in malignant hematological diseases, and affirm the early benefits of this amplification strategy. However, its long-term impact on patients still requires large-scale clinical studies. The emergence of Omidubicel pushes expanded umbilical cord blood transplantation to the forefront of transplantation treatment and regenerative medicine.

Key words: Omidubicel, Umbilical cord blood, Hematopoietic stem cells, In vitro expansion, Nicotinamide

图1 烟酰胺抑制SIRT1脱乙酰化反应注：Ac为乙酰基；Tyr为酪氨酸；NAD+为烟酰胺腺嘌呤二核苷酸；NAM为烟酰胺

图2 Omidubicel的制备流程

表1 Omidubicel相关临床试验数据

	CD34⁺细胞扩增倍数	CD34⁺细胞回输数量/ （×10⁶/kg）	中性粒细胞植入中位时间（d）	血小板植入中位时间（d）	100 d a-GVHD
Ⅰ期临床试验^[16]	72	3.5	13（25^*）	33（37^*）	45.5%
Ⅰ/Ⅱ期临床试验^[17]	33	6.3	11.5（21^*）	34（46^*）	44% （56%^*）
Ⅲ期临床试验^[18]	130	9.0	12（22^*）	37（50^*）	56% （43%^*）
	100 d Ⅲ-Ⅳa-GVHD	2年c-GVHD	2年OS率	2年PFS率	住院天数（d）
Ⅰ期临床试验^[16]	0	18.2%	82%^#	73%^#	26
Ⅰ/Ⅱ期临床试验^[17]	11% （27%^*）	40% （30%^*）	51% （48%^*）	43% （45%^*）	20
Ⅲ期临床试验^[18]	14% （21%^*）	35% （29%^*）	n.a	36%（45%^*）	27（35^*）

表1 Omidubicel相关临床试验数据

	CD34⁺细胞扩增倍数	CD34⁺细胞回输数量/ （×10⁶/kg）	中性粒细胞植入中位时间（d）	血小板植入中位时间（d）	100 d a-GVHD
Ⅰ期临床试验^[16]	72	3.5	13（25^*）	33（37^*）	45.5%
Ⅰ/Ⅱ期临床试验^[17]	33	6.3	11.5（21^*）	34（46^*）	44% （56%^*）
Ⅲ期临床试验^[18]	130	9.0	12（22^*）	37（50^*）	56% （43%^*）
	100 d Ⅲ-Ⅳa-GVHD	2年c-GVHD	2年OS率	2年PFS率	住院天数（d）
Ⅰ期临床试验^[16]	0	18.2%	82%^#	73%^#	26
Ⅰ/Ⅱ期临床试验^[17]	11% （27%^*）	40% （30%^*）	51% （48%^*）	43% （45%^*）	20
Ⅲ期临床试验^[18]	14% （21%^*）	35% （29%^*）	n.a	36%（45%^*）	27（35^*）

1	Tajer P, Pike-Overzet K, Arias S, et al. Ex vivo expansion of hematopoietic stem cells for therapeutic purposes: lessons from development and the niche[J]. Cells, 2019, 8(2):169.
2	Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood[J]. N Engl J Med, 1989, 321(17):1174-1178.
3	Sca D, Pjra D, Psla D, et al. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study[J].Lancet Haematol, 2020, 7(2):e134-e145.
4	Murata M, Maeda Y, Masuko M, et al. Phase II study of intrabone single unit cord blood transplantation for hematological malignancies[J]. Cancer Sci, 2017, 108(8):1634-1639.
5	Masaya, Okada, Taizo, et al. A prospective multicenter phase II study of intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning[J]. Eur J Haematol, 2018,100(4):335-343.
6	Bonifazi F, Dan E, Labopin M, et al. Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study[J]. Bone Marrow Transplant, 2019, 54(5):717-725.
7	Patterson AM, Plett PA, Sampson CH, et al. Prostaglandin E2 enhances aged hematopoietic stem cell function[J]. Stem Cell Rev Rep，2021, 17(5):1840-1854.
8	]Islami M, Payandeh Z, Abdolahinia ED, et al. Fucosylated umbilical cord blood hematopoietic stem cell expansion on selectin-coated scaffolds[J]. J Cell Physiol, 2019, 234(12):22593-22603.
9	Brunstein CG, Cutler CS, Defor TE, et al. Matching at human leukocyte antigen-c improved the outcomes after double umbilical cord blood transplantation for recipients of two to four of six human leukocyte antigen-matched grafts[J]. Biol Blood Marrow Transplant, 2017, 23(1):126-133.
10	Fuchs EJ, O'Donnell PV, Eapen M, et al. Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101)[J]. Blood, 2021,137(3):420-428.
11	Wilkinson AC, Ishida R, Kikuchi M, et al. Author Correction: Long-term ex vivo haematopoietic-stem-cell expansion allows nonconditioned transplantation[J]. Nature, 2019, 571(7766):E12.
12	Ghafouri-Fard S, Niazi V, Taheri M, et al. Effect of small molecule on ex vivo expansion of cord blood hematopoietic stem cells: a concise review[J]. Front Cell Dev Biol, 2021, 9:649115.
13	Peled T, Shoham H, Aschengrau D, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment[J]. Exp Hematol, 2012, 40(4):342-355.
14	Shen K, Pender CL, Bar-Ziv R, et al. Mitochondria as cellular and organismal signaling hubs[J]. Annu Rev Cell Dev Biol, 2022, 38:179-218.
15	Hu S, Luo J, Fu M , et al. Soluble epoxide hydrolase deletion attenuated nicotine-induced arterial stiffness via limiting the loss of SIRT1[J]. Am J Physiol Heart Circ Physiol, 2021, 321(2):H353-H368.
16	Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment[J]. J Clin Invest, 2014, 124(7):3121-3128.
17	Horwitz ME, Wease S, Blackwell B, et al. Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide[J]. J Clin Oncol, 2019, 37(5):367-374.
18	]Horwitz ME, Stiff PJ, Cutler CS, et al. Omidubicel versus standard myeloablative umbilical cord blood transplantation: results of a phase III randomized study[J]. Blood, 2021, 138(16):1429-1440.
19	Inoue Y, Okinaka K, Fuji S, et al.Severe acute graft-versus-host disease increases the incidence of blood stream infection and mortality after allogeneic hematopoietic cell transplantation: Japanese transplant registry study[J]. Bone Marrow Transplant, 2021, 56(9):2125-2136.
20	Koning CD, Langenhorst J, Kesteren CV, et al. Innate immune recovery predicts CD4⁺ T cell reconstitution after hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2019, 25( 4):819-826.
21	Koning CD, Tao W, Lacna A, et al. Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation[J]. Bone Marrow Transplant, 2021, 56(11):2826-2833.
22	Clara JA, Vo P, Aue G, et al. Ex vivo nicotinamide-expanded (NAM-Expanded) unrelated cord blood transplantation (UCB) for refractory severe aplastic anemia results in rapid engraftment and expedites immune recovery[J]. Biol Blood Marrow Transplant, 2019, 25(3):S210-S211.
23	Parikh S, Brochstein JA, Galamidi E, et al. Allogeneic stem cell transplantation with omidubicel in sickle cell disease[J]. Blood Adv, 2021, 5(3):843-852.
24	Sakurai M, Ishitsuka K, Ito R, et al. Chemically defined cytokine-free expansion of human haematopoietic stem cells[J]. Nature, 2023, 615(7950):127-133.
25	Araki D, Fu JF, Huntsman H, et al. NOTCH-mediated ex vivo expansion of human hematopoietic stem and progenitor cells by culture under hypoxia[J]. Stem Cell Reports, 2021,16(9):2336-2350.
26	Bucar S, Branco ADM, Mata MF, et al. Influence of the mesenchymal stromal cell source on the hematopoietic supportive capacity of umbilical cord blood-derived CD34⁺-enriched cells[J]. Stem Cell Res Ther, 2021,12(1):399.
27	Mathanda RR, Hamilton BK, Rybicki L, et al. Quality of life trajectories in adolescent and young adult versus older adult allogeneic hematopoietic cell transplantation recipients[J]. Biol Blood Marrow Transplant, 2020, 26(8):1505-1510.
28	Lin C, Sajeev G, Stiff PJ, et al. Health-related quality of life following allogeneic hematopoietic cell transplantation with omidubicel versus umbilical cord blood[J]. Transplant Cell Ther, 2023, 29(1):52.e1-52.e9.
29	Patel SA, Allewelt HA, Troy JD, et al. Durable chimerism and long-term survival after unrelated umbilical cord blood transplantation for pediatric hemophagocytic lymphohistiocytosis: a single-center experience[J]. Biol Blood Marrow Transplant, 2017, 23(10):1722-1728.
30	Lin C, Schwarzbach A, Sanz J, et al. Multicenter long-term follow-up of allogeneic hematopoietic cell transplantation with omidubicel: a pooled analysis of five prospective clinical trials[J]. Transplant Cell Ther, 2023, 29(5):338.e1-338.e6

[1]	何甘霖, 陈香侬, 李萍, 甄佳怡, 李京霞, 邹外一, 许多荣. 白血病异基因造血干细胞移植术后股骨坏死的影响因素[J/OL]. 中华关节外科杂志(电子版), 2024, 18(04): 450-456.
[2]	全勇, 冉新泽, 胡梦佳, 陈芳, 陈乃成, 廖伟年, 陈默, 申明强, 陈石磊, 王崧, 王军平. 低氧习服在小鼠造血干细胞急性放射损伤修复中的作用观察[J/OL]. 中华损伤与修复杂志(电子版), 2023, 18(04): 293-298.
[3]	刘云, 时月, 郭冬梅, 邱志远, 王丽娟, 冉学红, 李乾鹏. 造血干细胞移植治疗伴有胚系突变的髓系肿瘤患者三例并文献复习[J/OL]. 中华移植杂志(电子版), 2024, 18(04): 230-234.
[4]	朴美英, 刘娜, 孟繁峥, 李春艳. 支气管镜诊断儿童造血干细胞移植后闭塞性细支气管炎综合征二例[J/OL]. 中华移植杂志(电子版), 2024, 18(02): 116-119.
[5]	刘麾, 赵鹏, 冯静, 胡晓彦, 杜涛, 王凌云. 三维调强放射治疗对急性髓系白血病异基因造血干细胞移植后髓外复发的疗效观察[J/OL]. 中华移植杂志(电子版), 2024, 18(02): 110-115.
[6]	李赞, 许芝彬, 冯志金, 张雄. 重型β-地中海贫血患儿异基因造血干细胞移植后淋巴细胞亚群动态分析[J/OL]. 中华移植杂志(电子版), 2024, 18(01): 22-29.
[7]	孔欣, 宋宝全, 刘吟, 张剑, 仇惠英, 吴德沛. 异基因造血干细胞移植并发难治性呃逆一例[J/OL]. 中华移植杂志(电子版), 2023, 17(04): 253-255.
[8]	王向丽, 吴涛, 毛东锋, 刘恒, 刘文慧, 周芮, 田红娟. 异基因造血干细胞移植治疗ANKRD26相关性血小板减少症1例并文献复习[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(04): 236-238.
[9]	杜鑫, 刘霞霞, 张恬波, 张夏林, 杨林花, 张睿娟. AHNAK基因高表达与老年急性髓系白血病患者预后不良相关[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(04): 204-211.
[10]	张一健, 赵龙, 杨扬, 张贝贝, 张译予, 张斌. 造血干/祖细胞体外扩增和临床应用[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 122-127.
[11]	刘洋, 吴涛, 刘恒, 刘文慧, 田红娟, 周芮, 高铭敏, 王向丽, 张睿. 异基因造血干细胞移植治疗CSF3R基因突变急性髓系白血病M2型1例并文献复习[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 90-92.
[12]	詹卓, 晋佩佩, 张建敏, 何莉. 自体干细胞移植治疗POEMS综合征3例[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(01): 27-29.
[13]	崔光晶, 王肇光, 张雪梅, 夏洁芳, 李家梁, 盛凯, 任光强, 刘东. 组织获取位置和样本破损程度对胎盘来源造血干细胞质量的影响[J/OL]. 中华细胞与干细胞杂志(电子版), 2023, 13(06): 331-338.
[14]	刘文慧, 吴涛, 张曦. 间充质干细胞联合血小板生成素受体激动剂在异基因造血干细胞移植后血小板恢复中的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 242-246.
[15]	陈婷婷, 江学良, 余佳丽, 柯剑林. 干细胞治疗炎症性肠病的安全性[J/OL]. 中华消化病与影像杂志(电子版), 2023, 13(04): 193-198.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Clinical research and development progress of cord blood-derived product Omidubicel

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Clinical research and development progress of cord blood-derived product Omidubicel